Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Zhen Huo

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper

Papers 9

  1. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1007/s00464-020-07791-2↗
  2. Construction and integrated analysis of a lncRNA-associated competing endogenous RNA network reveal functional lncRNAs in pancreatic cancer. First author DOI 10.21037/tcr.2020.04.03↗
  3. Comparison of Radical Antegrade Modular Pancreatosplenectomy with Standard Retrograde Pancreatosplenectomy for Left-Sided Pancreatic Cancer: A Meta-Analysis an… Co-author DOI 10.12659/msm.914540↗
  4. TRIANGLE operation for borderline resectable pancreatic cancer in total pancreatectomy. First author DOI 10.21037/tcr.2019.09.50↗
  5. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Co-author DOI 10.2147/ott.s206039↗
  6. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  7. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  8. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  9. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16732↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 8 shared papers, 2017–2021 · strength 0.69
  2. Yuanchi Weng · 5 shared papers, 2019–2021 · strength 0.54
  3. Shuyu Zhai · 4 shared papers, 2019–2020 · strength 0.40
  4. Chenghong Peng · 5 shared papers, 2017–2021 · strength 0.40
  5. Xiaxing Deng · 4 shared papers, 2017–2021 · strength 0.38
  6. Xiaxing Deng · 4 shared papers, 2017–2020 · strength 0.35
  7. Xiaomei Tang · 4 shared papers, 2017–2019 · strength 0.32
  8. Xiongxiong Lu · 4 shared papers, 2017–2020 · strength 0.32
  9. Hao Qian · 3 shared papers, 2019 · strength 0.29
  10. Hongzhe Li · 4 shared papers, 2017–2018 · strength 0.27
  11. Xinjing Wang · 4 shared papers, 2017–2018 · strength 0.27
  12. Yuan Fang · 3 shared papers, 2017–2018 · strength 0.20
  13. Chenlei Wen · 3 shared papers, 2017–2018 · strength 0.20
  14. Shulin Zhao · 2 shared papers, 2019 · strength 0.19
  15. Weishen Wang · 2 shared papers, 2017–2020 · strength 0.18
  16. Yu Jiang · 1 shared paper, 2021 · strength 0.13
  17. Ningzhen Fu · 1 shared paper, 2021 · strength 0.13
  18. Jiabin Jin · 1 shared paper, 2021 · strength 0.13
  19. Hao Chen · 2 shared papers, 2017–2018 · strength 0.13
  20. Yuanbin Liu · 1 shared paper, 2020 · strength 0.12
  21. Yue Wang · 1 shared paper, 2020 · strength 0.12
  22. Dongfeng Cheng · 1 shared paper, 2017 · strength 0.06
  23. Qian Zhan · 1 shared paper, 2017 · strength 0.06
  24. Hao Chen · 1 shared paper, 2017 · strength 0.06
  25. Jing Xie · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.